OTC : FITY
$0.0 (-16.67%)
| Source | Headline |
|---|---|
|
Fifty 1 Labs Announces Strategic Evolution into Peptide Biotechnology and Telehealth
Company outlines dual platform spanning peptide R&D, AI-enabled discovery, and planned U.S. telehealth peptide services VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) (the "Company" or "Fifty 1 Labs") today announced that it is positioning itself as a peptide biotechnology and telehealth company focused on advancing peptide science, musculoskeletal ("MSK") health, recovery, and evidence-driven product innovation. The Company's emerging strategy integrates three complementary areas: peptide research and development, AI-enabled discovery workflows, and a planned U.S.-focused telehealth peptide services platform. accessnewswire.com - 2026-07-10 10:00:00 |